[Treatment of metastatic non small cell lung cancer]

First line standard treatment of metastatic non-small-cell lung cancer is based on intravenous chemotherapy. Chemotherapy has been demonstrated to increase survival, to reduce symptoms and to improve quality of life. Bevacizumab, a monoclonal antibody inhibiting angiogenesis, improves survival when combined with chemotherapy. Because of a risk of hemoptysis, bevacizumab can only be delivered to non-squamous tumours with no proximal vascular invasion. Systemic treatment decision results from a multidisciplinary discussion and takes into account both patient (mostly performance status, age, and comorbidity) and tumour characteristics (histology, tumor location).